TELA Bio, Inc.

NasdaqGM:TELA Voorraadrapport

Marktkapitalisatie: US$76.0m

TELA Bio Beheer

Beheer criteriumcontroles 2/4

De CEO TELA Bio is Antony Koblish, benoemd in Apr2012, heeft een ambtstermijn van 12.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.37M, bestaande uit 25.2% salaris en 74.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.22% van de aandelen van het bedrijf, ter waarde $ 929.27K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.2 jaar en 5 jaar.

Belangrijke informatie

Antony Koblish

Algemeen directeur

US$2.4m

Totale compensatie

Percentage CEO-salaris25.2%
Dienstverband CEO12.6yrs
Eigendom CEO1.2%
Management gemiddelde ambtstermijn3.2yrs
Gemiddelde ambtstermijn bestuur5yrs

Recente managementupdates

Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

May 29
Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

Recent updates

Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely

Nov 09
Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely

Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33%

Aug 19
Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33%

Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet?

Jul 03
Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet?

Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

May 29
Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward

May 23
TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward

Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Mar 24
Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)

Mar 08
Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)

TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?

Oct 07
TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?

Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult

Jul 31
Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult

TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption

Oct 02

Tela Bio prices $32M common stock offering

Aug 16

Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

May 12
Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

TELA Bio - Follow Up With Management

Jan 14

Our First Look At TELA Bio

Nov 04

TELA Bio Plugging Away

Oct 25

TELA Bio (TELA) Investor Presentation - Slideshow

May 26

Analyse CEO-vergoeding

Hoe is Antony Koblish's beloning veranderd ten opzichte van TELA Bio's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$42m

Jun 30 2024n/an/a

-US$42m

Mar 31 2024n/an/a

-US$40m

Dec 31 2023US$2mUS$595k

-US$47m

Sep 30 2023n/an/a

-US$44m

Jun 30 2023n/an/a

-US$44m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$2mUS$566k

-US$44m

Sep 30 2022n/an/a

-US$43m

Jun 30 2022n/an/a

-US$40m

Mar 31 2022n/an/a

-US$36m

Dec 31 2021US$2mUS$538k

-US$33m

Sep 30 2021n/an/a

-US$32m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$30m

Dec 31 2020US$806kUS$479k

-US$29m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$27m

Mar 31 2020n/an/a

-US$29m

Dec 31 2019US$2mUS$403k

-US$30m

Sep 30 2019n/an/a

-US$32m

Jun 30 2019n/an/a

-US$30m

Mar 31 2019n/an/a

-US$28m

Dec 31 2018US$569kUS$375k

-US$30m

Compensatie versus markt: De totale vergoeding ($USD 2.37M ) Antony } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 648.89K ).

Compensatie versus inkomsten: De vergoeding van Antony is gestegen terwijl het bedrijf verliesgevend is.

CEO

Antony Koblish (58 yo)

12.6yrs

Tenure

US$2,366,371

Compensatie

Mr. Antony Koblish is an Operating Partner of 1315 Capital LLC. Mr. Koblish serves as the President, Director and Chief Executive Officer of TELA Bio, Inc. since April 2012, which he co-founded in April 20...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Antony Koblish
Co-founder12.6yrsUS$2.37m1.22%
$ 929.3k
Roberto Cuca
CFO & COO3.2yrsUS$1.06m0.43%
$ 323.4k
Paul Talmo
Chief Technology Officerno dataUS$962.24k0.21%
$ 160.2k
Megan Smeykal
VP, Corporate Controller3.5yrsgeen gegevens0.033%
$ 25.0k
D. Ocasio
General Counsel & Corporate Secretary2.6yrsgeen gegevensgeen gegevens
Jennifer Armstrong
Senior Vice President of Human Resources2.8yrsgeen gegevensgeen gegevens
Gregory Firestone
Chief Commercial Officerno datageen gegevens0.23%
$ 176.2k
Michael Leonard
Senior Vice President of Technical Operations2.8yrsgeen gegevensgeen gegevens
Peter Murphy
Chief Commercial Officer4.8yrsUS$936.76k0.055%
$ 41.7k
Louisa Smith
Investor Relations Contact Officerno datageen gegevensgeen gegevens

3.2yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TELA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Antony Koblish
Co-founder12.6yrsUS$2.37m1.22%
$ 929.3k
Vincent Burgess
Independent Director11.9yrsUS$128.59k0.045%
$ 34.2k
Federica O'Brien
Independent Director5yrsUS$133.59k0.025%
$ 19.3k
Douglas Evans
Independent Chairman of the Board4.6yrsUS$161.09k0.025%
$ 19.3k
Lisa Colleran
Independent Director4.6yrsUS$133.59k0.025%
$ 19.3k
Kurt Azarbarzin
Independent Director6yrsUS$121.09k0.025%
$ 19.3k
Jeffrey Blizard
Directorless than a yeargeen gegevensgeen gegevens

5.0yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TELA wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).